We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $6.05B
1-Year Est. Return 76.64%
This Fund
S&P 500
This Quarter Est. Return
+11.85%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$1.51B
AUM Growth
-$26.5M
Cap. Flow
-$152M
Cap. Flow %
-10.08%
Top 10 Hldgs %
28.6%
Holding
136
New
8
Increased
26
Reduced
33
Closed
15

Top Buys

Rank Stock Value
1
TWLO icon
Twilio
TWLO
+$20.1M
2
W icon
Wayfair
W
+$13.8M
3
VMC icon
Vulcan Materials
VMC
+$13.5M
4
AIMT
Aimmune Therapeutics
AIMT
+$6.36M
5
XLRN
Acceleron Pharma
XLRN
+$5.93M

Top Sells

Rank Stock Value
1
MBLY
Mobileye N.V.
MBLY
+$33.3M
2
LEA icon
Lear
LEA
+$23.6M
3
ABBV icon
AbbVie
ABBV
+$17.9M
4
ATHN
Athenahealth, Inc.
ATHN
+$17.5M
5
BWA icon
BorgWarner
BWA
+$17.4M

Sector Composition

Rank Sector Weight
1 Healthcare 33.11%
2 Consumer Discretionary 15.23%
3 Technology 14.9%
4 Industrials 11.42%
5 Utilities 4.55%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KITE
51
DELISTED
Kite Pharma, Inc.
KITE
$10M 0.67%
128,000
– –
STML
52
DELISTED
Stemline Therapeutics, Inc.
STML
$9.29M 0.62%
1,086,400
+235,000
+28% +$2.14M
XNCR icon
53
Xencor
XNCR
$1.59B
$8.23M 0.54%
344,000
– –
ONCE
54
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$8M 0.53%
150,000
– –
DBVT
55
DBV Technologies
DBVT
$817M
$7.85M 0.52%
22,300
-2,660
-11% -$934K
GWPH
56
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$7.68M 0.51%
63,500
– –
EPIX
57
DELISTED
ESSA Pharma
EPIX
$7.41M 0.49%
135,971
– –
PANW icon
58
Palo Alto Networks
PANW
$265B
$7.32M 0.48%
390,000
-240,000
-38% -$5.37M
ASND icon
59
Ascendis Pharma A/S
ASND
$16.5B
$6.89M 0.46%
246,100
+17,100
+7% +$432K
AIMT
60
DELISTED
Aimmune Therapeutics
AIMT
$6.74M 0.45%
+310,000
New +$6.36M
PRTA icon
61
Prothena Corp
PRTA
$440M
$6.7M 0.44%
120,000
– –
BMRN icon
62
BioMarin Pharmaceuticals
BMRN
$11.7B
$6.58M 0.44%
75,000
– –
CERN
63
DELISTED
Cerner Corp
CERN
$6.37M 0.42%
108,200
– –
AVXS
64
DELISTED
AveXis, Inc. Common Stock
AVXS
$6.16M 0.41%
+81,000
New +$5.01M
GBT
65
DELISTED
Global Blood Therapeutics, Inc.
GBT
$6.08M 0.4%
165,000
– –
EXR icon
66
Extra Space Storage
EXR
$31.3B
$6.06M 0.4%
81,500
– –
RARE icon
67
Ultragenyx Pharmaceutical
RARE
$2.56B
$5.92M 0.39%
87,400
– –
ATHN
68
DELISTED
Athenahealth, Inc.
ATHN
$5.77M 0.38%
51,200
-150,000
-75% -$17.5M
SAGE
69
DELISTED
Sage Therapeutics
SAGE
$5.76M 0.38%
81,000
-89,000
-52% -$5.21M
TTPH
70
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$5.51M 0.37%
30,000
– –
NBIX icon
71
Neurocrine Biosciences
NBIX
$18.7B
$5.41M 0.36%
125,000
– –
INCY icon
72
Incyte
INCY
$24.9B
$5.35M 0.35%
40,000
– –
EPZM
73
DELISTED
Epizyme, Inc
EPZM
$4.72M 0.31%
275,000
– –
ALNY icon
74
Alnylam Pharmaceuticals
ALNY
$27.4B
$4.61M 0.31%
90,000
– –
LKFT
75
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.81B
$4.48M 0.3%
52,000
– –
1 2
3
4 5

Similar funds

HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return

Eventide Asset Management's Q1 2017 Portfolio in Review

As of Q1 2017, Eventide Asset Management held 136 positions worth $1.51B, down 1.7% from $1.54B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Eventide Asset Management withdrew a net $152M in Q1 2017, closing 15 positions and reducing 33 holdings. Its most notable exit was Mobileye N.V., an estimated $33.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, down from 33% a quarter earlier, followed by Consumer Discretionary and Technology.

Against the trend, Eventide Asset Management opened a new position in Twilio worth $19.2M.

  • Eventide Asset Management's largest Q1 2017 buy was Twilio: 665,000 shares worth $19.2M.
  • Eventide Asset Management added most to Wayfair in Q1 2017, an estimated $13.8M increase.
  • Eventide Asset Management's biggest Q1 2017 reduction was Lear, cutting an estimated $23.6M.
  • Eventide Asset Management fully exited Mobileye N.V. in Q1 2017, selling an estimated $33.3M.
  • Eventide Asset Management's ten largest holdings make up 29% of its $1.51B portfolio in Q1 2017.
  • Eventide Asset Management opened 8 new positions and closed 15 in Q1 2017.
  • Eventide Asset Management's portfolio value fell 1.7% quarter-over-quarter to $1.51B.

Based on Eventide Asset Management's 13F filing for Q1 2017, filed 15 May 2017.